0000000000218475

AUTHOR

Simona Amodeo

0000-0002-2980-7372

showing 7 related works from this author

Comorbidities impact and de-prescribing in elderly with HCV-related liver disease: analysis of a prospective cohort.

2021

AbstractManagement for HCV has undergone a notable change using direct-acting antiviral drugs (DAAs), which are safe and effective even in elderly. Here, we define impact of comorbidities, concomitant medication and drug–drug interactions in elder patients with HCV related disease before starting DAAs regimen. We analyzed data of 814 patients prospectively enrolled at our Unit within the web based model HCV Sicily Network. Out of 814, 590 were treated with DAAs and 414 of them were older than 65 years. We divided those 414 in two groups, one including 215 patients, aged between 65 and 74 years, and another with 199 patients, aged of 75 years and over. Charlson Comorbidity Index (CCI) was as…

Malemedicine.medical_specialtySettore MED/09 - Medicina InternaComorbidityHepacivirusDDI int eractionAntiviral AgentsCo-morbiditieDe-prescribing03 medical and health sciencesLiver diseaseElderly0302 clinical medicineQuality of lifeInternal medicineDiabetes mellitusInternal MedicinemedicineHumans030212 general & internal medicineProspective StudiesProspective cohort studyDepression (differential diagnoses)Agedbusiness.industryCharlson IndexHepatitis C Chronicmedicine.diseaseRegimenHCVEmergency MedicineQuality of Life030211 gastroenterology & hepatologyFemalebusinessDyslipidemiaKidney diseaseInternal and emergency medicine
researchProduct

The Changing Epidemiology of Hepatocellular Carcinoma :  Experience of a Single Center

2019

Aims. To analyze the main etiological factors and some clinical features of patients with hepatocellular carcinoma (HCC) at diagnosis and to compare them with those we described ten years ago. Materials and Methods. We compared two groups of patients with HCC, Group 1 consisting of 132 patients (82 M, 50 F) diagnosed in the 2003–2008 period and Group 2 including 119 patients (82 M, 37 F) diagnosed in the 2013–2018 period. For all patients, age, sex, viral markers, alcohol consumption, serum alpha-fetoprotein (AFP) levels, and the main liver function parameters were recorded. The diagnosis of HCC was based on AASLD, EASL guidelines. The staging was classified according to the “Barcelona Clin…

Malemedicine.medical_specialtyCarcinoma HepatocellularSettore MED/09 - Medicina InternaArticle SubjectSingle CenterGastroenterologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesEpidemiology Hepatocellular carcinoma HCV HBV NASH0302 clinical medicineRisk FactorsInternal medicineEpidemiologyHumansMedicineStaging systemAgedNeoplasm StagingGeneral Immunology and Microbiologybusiness.industryLiver NeoplasmsRGeneral MedicineHepatitis Bmedicine.diseaseHepatitis Cdigestive system diseases030220 oncology & carcinogenesisHepatocellular carcinomaEtiologyMedicineViral MarkersFemale030211 gastroenterology & hepatologyalpha-FetoproteinsLiver functionbusinessLiver cancerResearch ArticleBioMed Research International
researchProduct

COVID in 2022. Clinical risk management of sars-cov-2 positive patients admitted to an internal medicine ward

2022

General Medicineinternal medicine wardSars-Cov 2risk managementGeneral Biochemistry Genetics and Molecular BiologyCovid
researchProduct

Outcome predictors in SARS-CoV-2 disease (COVID-19): The prominent role of IL-6 levels and an IL-6 gene polymorphism in a western Sicilian population

2022

Microbiology (medical)Polymorphism GeneticSettore MED/09 - Medicina InternaInfectious DiseasesCOVID-19.Interleukin-6SARS-CoV-2HumanJournal of Infection
researchProduct

EVOO's Effects on Incretin Production: Is There a Rationale for a Combination in T2DM Therapy?

2022

Type 2 diabetes mellitus (T2DM) is a serious public health concern as it is one of the most common chronic diseases worldwide due to social and economic developments that have led to unhealthy lifestyles, with a considerable impact both in terms of morbidity and mortality. The management of T2DM, before starting specific therapies, includes cornerstones such as healthy eating, regular exercise and weight loss. Strict adherence to the Mediterranean diet (MedDiet) has been related to an inverse association with the risk of T2DM onset, as well as an improvement in glycaemic control; in particular, thanks to the consumption of extra virgin olive oil (EVOO). Agonists of gut-derived glucagon-like…

Blood GlucoseDipeptidyl-Peptidase IV InhibitorsHypoglycemic Agent[SDV]Life Sciences [q-bio]Organic ChemistryEVOOT2DMGeneral MedicineIncretinIncretinsCatalysisComputer Science ApplicationsInorganic ChemistryDiabetes Mellitus Type 2Glucagon-Like Peptide 1Insulin SecretionHumansHypoglycemic AgentsMedDietPhysical and Theoretical ChemistryGLP-1Molecular BiologySpectroscopyHuman
researchProduct

Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER …

2021

Background: Direct-acting antivirals are highly effective for the treatment of hepatitis C virus (HCV) infection, regardless race/ethnicity. We aimed to evaluate demographic, virological and clinical data of HCV-infected migrants vs. natives consecutively enrolled in the PITER cohort. Methods: Migrants were defined by country of birth and nationality that was different from Italy. Mann-Whitney U test, Chi-squared test and multiple logistic regression were used. Results: Of 10,669 enrolled patients, 301 (2.8%) were migrants: median age 47 vs. 62 years, (p < 0.001), females 56.5% vs. 45.3%, (p < 0.001), HBsAg positivity 3.8% vs. 1.4%, (p < 0.05). Genotype 1b was prevalent in both gro…

MaleHCV genotypesEthnic groupLinked-to-care patientComorbidityHepacivirusLogistic regressionmedicine.disease_causeComorbidities; Direct acting antivirals; HCV Cohort; Linked-to-care patients; Aged; Antiviral Agents; Coinfection; Comorbidity; Female; Hepacivirus; Hepatitis C Chronic; Humans; Italy; Male; Middle Aged; Transients and MigrantsComorbidities0302 clinical medicineMedicineComorbidities; Direct acting antivirals; HCV Cohort; Linked-to-care patientsChronicTransients and MigrantsCoinfectionGastroenterologyvirus diseasesMiddle AgedHepatitis CLife evaluationItaly030220 oncology & carcinogenesisLinked-to-care patientsCohort030211 gastroenterology & hepatologyFemaleComorbiditieHumanHepatitis C virusSettore MED/12 - GASTROENTEROLOGIAAntiviral AgentsDirect acting antivirals03 medical and health sciencesDisease severityHumansAgedAntiviral AgentHepaciviruHepatologybusiness.industrySettore MED/09 - MEDICINA INTERNAHepatitis C Chronicmedicine.diseaseComorbiditydigestive system diseasesDirect acting antiviralHCV CohortbusinessDemography
researchProduct

SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease

2022

Non-alcoholic fatty liver disease (NAFLD), the most frequent liver disease in the Western world, is a common hepatic manifestation of metabolic syndrome (MetS). A specific cure has not yet been identified, and its treatment is currently based on risk factor therapy. Given that the initial accumulation of triglycerides in the liver parenchyma, in the presence of inflammatory processes, mitochondrial dysfunction, lipotoxicity, glucotoxicity, and oxidative stress, can evolve into non-alcoholic steatohepatitis (NASH). The main goal is to identify the factors contributing to this evolution because, once established, untreated NASH can progress through fibrosis to cirrhosis and, ultimately, be co…

Carcinoma HepatocellularSettore MED/09 - Medicina Internatype 2 diabetes mellituSGLT2metabolic syndromeCatalysisInorganic ChemistryNon-alcoholic Fatty Liver DiseaseNAFLDAnimalsHumansHypoglycemic AgentsPhysical and Theoretical ChemistrySodium-Glucose Transporter 2 InhibitorsMolecular BiologySpectroscopyDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentLiver NeoplasmsOrganic Chemistrynutritional and metabolic diseasesGeneral Medicinedigestive system diseasesComputer Science ApplicationsGlucoseLiverDiabetes Mellitus Type 2HumanInternational Journal of Molecular Sciences
researchProduct